2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1471

Polyautoimmunity and Major Organ Involvement Prevalence in Sjögren´s Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1329

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1569

Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1716

Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1343

Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1463

Positive Rate of Small Intestinal Bacterial Overgrowth Test (SIBO) Was Significant Correlations to Disease Activity of Primary Sjogren’s Syndrome (pSS)

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1411

Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1346

Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

9:00AM-11:00AM: Abstract Number: 1147

Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients

Healthcare Disparities In Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 1198

Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1747

Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 1445

Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1084

Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1519

Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1390

Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels

RA – Treatments Poster II: Established Treatments

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].